Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1999-05-27
2001-02-20
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S413000, C514S433000, C514S912000, C514S213010
Reexamination Certificate
active
06191126
ABSTRACT:
BACKGROUND OF THE INVENTION
Pain is a perceived nociceptive response to local stimuli in the body. The perception of pain at the level of the central nervous system requires the transmission of painful stimuli by peripheral sensory nerve fibers. Upon stimulation of tissue (i.e., thermal, mechanical or chemical), electro-chemical signals are transmitted from the sensory nerve endings to the spinal column, and hence to the brain where pain is perceived.
The cornea is highly innervated with sensory afferents which transmit various painful stimuli to the central nervous system. Pain conditions involving the eye, therefore, can arise in numerous instances, such as: foreign body stimulus, inflammation, dry eye syndrome, accidental trauma, surgical procedures and post-surgical recovery. For example, ocular pain can result from photorefractive keratotomy (“PRK”), a vision correcting, surgical procedure whereby a laser is used to shape the cornea. This process involves the photoablation of Bowman's membrane and the stromal levels of the cornea. As a result, the denuding of the nerve-containing epithelial layers of the cornea can cause some patients to experience pain following laser surgery until the epithelium regenerates.
Various therapies have been attempted for the alleviation of pain. The use of non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac, have been developed to treat pain. These agents inhibit cyclooxygenase dependent prostaglandin synthesis. Prostaglandins can modulate pain perception at the level of the central nervous system and systemic administration of NSAIDs is known to provide analgesia. However, the use of NSAIDs can involve undesired side effects including gastrointestinal bleeding and kidney dysfunction.
Local anesthetics are another class of pain modulators which relieve pain by directly inhibiting nerve cellular function. One problem with local anesthetic therapy is that the anesthetics exhibit a short duration of action. Another problem with the use of local anesthetics is that their mechanism of action, non-specific membrane stabilization, can have the undesired coincident effect of also inhibiting biological functions of other cells, such as fibroblasts and surrounding neural cells. Therefore, even though pain sensation can be abated with local anesthetic treatment, healing and normal function of the tissue may be significantly compromised. There is a need, therefore, to discover agents which potently and specifically inhibit the transmission of painful stimuli by sensory afferents, without local anesthetic activity, following topical ocular application.
Other agents have also been suggested for use in treating pain. Such agents include tricyclic antidepressants such as imipramine and desipramine, alpha-2 adrenergic agonists, serotonin uptake blockers, such as prozac, and other analgesics such as paracetamol, as described in U.S. Pat. No. 5,270,050 (Coquelet et al.). Some of these therapies, however, have been associated with side-effects such as dryness of mouth, drowsiness, constipation, and low potencies and efficacies.
Opiates are another class of compounds used to treat pain. Opiates can be administered in a number of ways. For example, opiates can be administered systematically, by intravenous injection or oral dosage, or locally, by subcutaneous, intramuscular or topical application. Systemic administration of opiates, however, has been associated with several problems including dose escalation (tolerance), addiction, respiratory depression and constipation.
“Opioids” is a generic term of art used to describe molecules that produce morphine-like activity in the body. Opioid receptors are membrane proteins which generally cause analgesic responses when bound by opioids. There are three major categories of opioid receptors, designated &mgr; (mu), &kgr; (kappa) and &dgr; (delta). Other sub-type receptors appear to exist as well. Opioid receptors have been differentiated among each other by the preferential binding affinities of different agonists and antagonists, and by the different responses obtained from each receptor's binding. For example, the full agonist morphine has a ten times greater affinity for the mu receptor than for the delta and kappa receptors. Thus, morphine is a mu agonist (See,
Goodman and Gilman's Pharmacological Basis of Therapeutics
(8th Edition), Jaffee,
Chapter
21:
Opioid Analgesics And Antagonists
, page 485-492 (1993).) Kappa receptors have also been delineated from the general class of opioid receptors by the fact that mu and delta receptor agonists increase membrane potassium conductance and decrease the duration of presynaptic action potential, whereas kappa receptor agonists decrease voltage-dependent calcium conductance without affecting potassium conductance (Kanemasa,
k
-
opioid agonist U
50488
inhibits P
-
type Ca
2+
channels by two mechanisms, Brain Research
, volume 707, pages 207-212 (1995)).
While it is known that opiate analgesics such as morphine relieve pain by activating specific receptors in the brain, recent studies demonstrate the analgesic effects of compounds which act on kappa receptors in peripheral tissue. (See, Joris et al.,
Opiates suppress carrageenan
-
induced edema and hypothermia at doses that inhibit hyperalgesia, Pain
, volume 43, pages 95-103 (1990); Eisenberg,
The peripheral antinociceptiave effect of morphine in a rat model of facial pains, Neuroscience
, volume 72, No. 2, pages 519-575 (1996); and Gohschlich,
The peripherally acting k
-
opiate agonist EMD
61753
and analogues: opioid activity versus peripheral selectivity, Drugs Exptl. Clin. Res.
, volume XX1(5), pages 171-174 (1995)).
SUMMARY OF THE INVENTION
The present invention is directed to compositions and methods of treating ocular pain. The present invention is based in part on the finding that compounds which bind to kappa opioid receptors in the eye inhibit ocular pain. More specifically, the present invention provides compositions containing kappa opioid agonists for the treatment of ocular pain.
The methods of the present invention involve the topical dosage of the compositions described below. One advantage of this therapy is that the inhibition of pain is receptor-specific, as contrasted with non-specific therapy, such as local anesthetic treatment. This specific activity may reduce greatly the number of dosings per day, and also reduce other drawbacks such as short duration of action and inhibition of wound healing, which are associated with local anesthetics. Additionally, kappa opioid receptor binding agents acting locally within ocular tissue avoid the problems of tolerance, addiction and constipation associated with the chronic, systemic administration of opiates.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to the use of kappa opioid receptor agonists for the prevention or alleviation of pain. It has now been found that kappa opioid agonists potently prevent or alleviate ocular pain. The kappa opioid receptor is found principally in the spinal cord, but recent evidence of other peripherally located kappa receptors has been reported, as described above.
The compounds of the present invention are kappa opioid receptor agonists. As used herein, a “kappa opioid agonist” refers to a compound which activates a kappa opioid receptor. Other opioid receptor agonists, such as mu and delta are excluded from the present invention compounds.
The kappa opioid receptor agonists of the present invention are known or may be elucidated by various biological binding studies known in the art. For example, the kappa opioid agonists of the present invention may be ascertained by displacement studies involving the binding of known radioactive agonists, such as U69593, with target tissue slices or homogenates (Gohschlich,
Drugs Exptl. Clin. Res.
, Volume XX1(5), pages 171-174 (1995)).
The following compounds are examples of kappa opioid agonists, listed as their trade name
umber: enadoline, ICI-199441, R-84760, ZT-52656A, tifluadom, PD-117302, PD-129290, MR-1268, KT-9
Alcon Laboratories Inc.
Fay Zohreh
Mayo Michael C.
Ryan Patrick M.
LandOfFree
Topical use of &kgr; opioid agonists to treat ocular pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical use of &kgr; opioid agonists to treat ocular pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical use of &kgr; opioid agonists to treat ocular pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2613702